the aid library

LIST OPTIONS

Filter

7197

Sort by:

Direction:

Download (1396)

View PDF (3139)

Policy guidelines: Child and adolescent mental health

Department of Health, South Africa (2013) C2

The guidelines begin with an overview of the determinants of mental health among children and adolescents before reviewing related South African policies and legislation. The document then discusses strategies to build skills among caregivers, teachers and other frontline providers of mental health ... more

Download (64)

View PDF (104)

Policy Analysis and Advocacy Decision Model for HIV-Related Services

B. Pick; D. Wolfe; D. Burrows; F. Hariga; et al. USAID (From the American People); REPFAR; EURASIAN Harm Reduction Network; Health Policy Project (2012) C2

People Who Inject Drugs In addition, the following individuals of our external expert advisory committee made instrumental contributions to the initial design and content of the document: Billy Pick, USAID; Daniel Wolfe, Open Society Foundations; Dave Burrows, AIDS Projects Management Group; Fabi... more

Download (68)

View PDF (108)

Situation Analysis and Recommendations: Antibiotic Use and Resistance in Kenya

Kenya Medical Research Institute (2011) C2

In Kenya, the bacterial infections that contribute most to human disease are often those in which re-‐sistance is most evident. Examples are multidrug-‐resistant enteric bacterial pathogens such as typhoid, ... more

Download (1640)

View PDF (1455)

mhGAP Training Manuals - for the mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings, version 2.0
recommended

World Health Organization WHO WHO (2017) C_WHO

As part of the Mental Health Gap Action Programme, WHO has developed training manuals (Training of trainers and supervisors training manual and Training of health-care providers training manual) to support implementation of the mhGAP Intervention Guide for mental, neurological and substance use (MNS... more

Download (383)

View PDF (2843)

UNHCR’s mental health and psychosocial support

Meyer, S. UNHCR (2013) C2

A broad range of UNHCR’s key priorities overlap with MHPSS issues – for example, child protection and sexual and gender-based violence [SGBV] prevention and response. Despite all these existent synergies, UNHCR’s current policies and guidelines do not sufficiently link with MHPSS principles.... more

Download (51)

View PDF (271)

Molecular and Clinical Aspects of Chronic Manifestations in Chagas Disease: A State-of-the-Art Review

Medina-Rincón, G.; Gallo-Bernal, S.; Jiménez, P.; et al. (2021) CC

Pathogens . 2021 Nov 16;10(11):1493.doi: 10.3390/pathogens10111493 .Chronic manifestations of Chagas disease present as disabling and life-threatening condi-tions affecting mainly the cardiovascular and gastrointestinal systems. Although meaningful research has outlined the different molecular mech... more

Download (925)

View PDF (1534)

Guidelines Storage Essential Medicines And Other Health Commodities

World Health Organization WHO; Deliver; UNICEF (2006) C_WHO

Maintaining proper storage conditions for health commodities is vital to ensuring their quality. Product expiration dates are based on ideal storage conditions and protecting product quality until their expiration date is important for serving customers and conserving resources. Guidelines for the S... more

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (86)

View PDF (94)

7 Ways Dentists Can Act Against Antibiotic Resistance

Centers for Disease Control and Prevention CDC (2019) C_CDC

Dentists are uniquely positioned to play a role in pre enting the spread of antibiotic resistance. Here are se en simple “how-tos” for safe, appropriate antibiotic prescribing and use when treating dental infections

Download (575)

View PDF (679)

Chikungunya. Clinical managemement in dengue-endemic areas

Centers for Disease Control and Prevention (2014)

Download (929)

View PDF (1661)

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, 12 September 2019

Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children AIDSinfo (2019) CC

Updated guidelines

Download (377)

View PDF (1728)

Guidance on chlamydia control in Europe

European Centre for Disease Prevention and Control (2016) C1

This document updates the 2009 ECDC guidance on chlamydia control in Europe. It was developed by a technical expert group which conducted a critical review of the scientific evidence on the epidemiology of chlamydia and the effectiveness of screening programmes. The aim of this guidance is to suppo... more

Download (308)

View PDF (617)

CDC in Sierra Leone: Factsheet

Centers for Disease Control and Prevention (CDC) (2015) C_CDC

mhGAP Training Manuals - for the mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings, version 2.0 recommended

mhGAP Training Manuals - for the mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings, version 2.0
recommended